KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Assets (2016 - 2025)

Astrazeneca has reported Assets over the past 11 years, most recently at $114.1 billion for Q4 2025.

  • Quarterly results put Assets at $114.1 billion for Q4 2025, up 9.65% from a year ago — trailing twelve months through Dec 2025 was $114.1 billion (up 9.65% YoY), and the annual figure for FY2025 was $114.1 billion, up 9.65%.
  • Assets for Q4 2025 was $114.1 billion at Astrazeneca, up from $104.0 billion in the prior quarter.
  • Over the last five years, Assets for AZN hit a ceiling of $114.1 billion in Q4 2025 and a floor of $104.0 million in Q4 2021.
  • Median Assets over the past 5 years was $96.5 billion (2022), compared with a mean of $63.0 billion.
  • Biggest five-year swings in Assets: skyrocketed 92672.12% in 2022 and later crashed 99.68% in 2023.
  • Astrazeneca's Assets stood at $104.0 million in 2021, then skyrocketed by 92672.12% to $96.5 billion in 2022, then crashed by 99.68% to $313.0 million in 2023, then skyrocketed by 33138.02% to $104.0 billion in 2024, then increased by 9.65% to $114.1 billion in 2025.
  • The last three reported values for Assets were $114.1 billion (Q4 2025), $104.0 billion (Q4 2024), and $313.0 million (Q4 2023) per Business Quant data.